Iranian Journal of Basic Medical Sciences

Iranian Journal of Basic Medical Sciences

Harmaline improves diabetes-associated renal alterations in nicotinamide/streptozotocin-induced diabetic mice: Possible involvement of oxidative stress, inflammation, and renin–angiotensin system signaling

Articles in Press

Document Type : Original Article

Authors
Farima Malekinia 1
Akram Ahangarpour 2
Khojasteh Hoseinynejad 3
Seyyed Ali Mard 3
Maryam Radan 3
Fereshteh Nejaddehbashi 4
1 Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Diabetes Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Persian Gulf Physiology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
10.22038/ijbms.2026.95151.20519
Abstract
Objective(s): Diabetic nephropathy (DN) is marked by structural and functional kidney damage, driven by oxidative stress, inflammation, and renin–angiotensin system (RAS) dysregulation. Harmaline (HAR), a β-carboline alkaloid with potent antioxidant and anti-inflammatory properties, is a promising multi-target therapeutic candidate.
Materials and Methods: Twenty-four male mice were randomized into vehicle control (CO), diabetic (DI; nicotinamide 120 mg/kg+streptozotocin 65 mg/kg), diabetic treated with HAR (DI/HAR; 30 mg/kg), or diabetic treated with metformin (DI/MET; 150 mg/kg). After ten days, renal tissues and blood were analyzed for oxidative stress, inflammatory and RAS markers, microRNA expression, and histopathological alterations.
Results: Harmaline reversed the changes in total oxidant status and malondialdehyde levels in kidney tissue of diabetic mice. Histopathological analysis showed significant improvement in kidney injury in diabetic mice receiving harmaline. Harmaline treatment decreased the expression of miR-125b, nuclear factor kappa B (NF-κB), tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Also, in the antioxidant pathway, there was an increase in the levels of miR-200a, nuclear factor erythroid-related2 (Nrf2), and NAD(P)H quinone dehydrogenase 1 (Nqo1), and a decrease in ECH-like chelate-associated protein1 (Keap1) in kidney tissue. This treatment also decreased the expression of angiotensin-converting enzyme 1 (ACE1) and angiotensin II receptor 1 (AT1R), as well as angiotensin II levels.
Conclusion: Harmaline confers renoprotection in experimental DN by simultaneously regulating oxidative stress, inflammatory signaling, and RAS pathways, supporting its potential as a multi-target therapeutic strategy. This study highlights HAR as a promising candidate for translational intervention in diabetic kidney disease.
Keywords
Diabetic nephropathy
Harmaline
Inflammation
MicroRNAs
NF-kappa B
Nuclear factor E2-related factor 2
Oxidative stress
Subjects
1. Chyła G, Sałaga-Zaleska K, Dąbkowski K, Kuchta A, Jankowski M. Suramin enhances the urinary excretion of VEGF-A in normoglycemic and streptozotocin-induced diabetic rats. Pharmacol Rep 2021; 73:841-846.
2. Chen J, Zhang Q, Guo J, Gu D, Liu J, Luo P, et al. Single-cell transcriptomics reveals the ameliorative effect of rosmarinic acid on diabetic nephropathy-induced kidney injury by modulating oxidative stress and inflammation. Acta Pharm Sin B 2024; 14:1661-1676.
3. Jin Q, Liu T, Qiao Y, Liu D, Yang L, Mao H, et al. Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols. Fron Immunol 2023; 14:1185317.
4. Hammad M, Raftari M, Cesário R, Salma R, Godoy P, Emami SN, et al. Roles of oxidative stress and Nrf2 signaling in pathogenic and non-pathogenic cells: A possible general mechanism of resistance to therapy. Antioxidants 2023; 12:1371.
5. Suzuki T, Takahashi J, Yamamoto M. Molecular basis of the KEAP1-NRF2 signaling pathway. Mol Cells 2023; 46:133-141.
6. Villeneuve NF, Lau A, Zhang DD. Regulation of the Nrf2–Keap1 antioxidant response by the ubiquitin proteasome system: An insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal 2010; 13:1699-1712.
7. Chen F, Xiao M, Hu S, Wang M. Keap1-Nrf2 pathway: A key mechanism in the occurrence and development of cancer. Frontiers in oncology 2024; 14:1381467.
8. Tossetta G, Fantone S, Piani F, Crescimanno C, Ciavattini A, Giannubilo SR, et al. Modulation of NRF2/KEAP1 signaling in preeclampsia. Cells 2023; 12:1545.
9. Li Y-B, Fu Q, Guo M, Du Y, Chen Y, Cheng Y. MicroRNAs: Pioneering regulators in Alzheimer’s disease pathogenesis, diagnosis, and therapy. Transl Psychiatry 2024; 14:367.
10. Yan J, Gu Q, Li J, Zhou Z, Jiang W, Guan W, et al. MS-275 facilitates osseointegration in osteoporotic rats by mitigating oxidative stress via activation of the miR-200a/Keap1/Nrf2 signaling pathway. Redox Rep 2025; 30:2466142.
11. Syed RU, Moni SS, Hussein W, Alhaidan TMS, Abumilha SMY, Alnahdi LK, et al. Effect of cubebin against streptozotocin-induced diabetic nephropathy rats via Inhibition TNF-α/NF-κB/TGF-β: In vivo and in Silico study. Sci Rep 2025; 15:4369.
12. Shen J, Dai Z, Li Y, Zhu H, Zhao L. TLR9 regulates NLRP3 inflammasome activation via the NF-kB signaling pathway in diabetic nephropathy. Diabetol Metab Syndr 2022; 14:26.
13. Karimi F, Maleki M, Movahedpour A, Alizadeh M, Kharazinejad E, Sabaghan M. Overview of the renin-angiotensin system in diabetic nephropathy.  J Renin Angiotensin Aldosterone Syst 2024; 25:14703203241302966.
14. Sanglard A, Miranda BCB, Vieira ALF, Macedo MVM, Santos RL, Campos ASRR, et al. The role of renin-angiotensin system in diabetic nephropathy: An update. Mini Rev Med Chem 2025; 25:591-600.
15. Yuan Q, Tang B, Zhang C. Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduct Target Ther 2022; 7:182.
16. Chaubey S, Singh L. Harmaline attenuates pain and inflammation: role of IL-1β, oxidative stress, nitric oxide and cyclo-oxygenase. Naunyn Schmiedebergs Arch Pharmacol 2025:1-13.
17. Li S-P, Wang Y-W, Qi S-L, Zhang Y-P, Deng G, Ding W-Z, et al. Analogous β-carboline alkaloids harmaline and harmine ameliorate scopolamine-induced cognition dysfunction by attenuating acetylcholinesterase activity, oxidative stress, and inflammation in mice. Front Pharmacol 2018; 9:346.
18. Senhaji S, Lamchouri F, Akabli T, Toufik H. In vitro anti-oxidant activities of five β-carboline alkaloids, molecular docking, and dynamic simulations. Struct Chem 2022; 33:883-895.
19. Elamin N, Fadlalla I, Omer S, Ibrahim H. Histopathological alteration in STZ-nicotinamide diabetic rats, a complication of diabetes or a toxicity of STZ. Int J Diabetes Clin Res 2018; 5:1-8.
20. Rashidi M, Mahmoudian E, Mirzaei S, Mazloomi SN, Bazi A, Azadeh H, et al. Harmaline downregulates angiogenesis markers and suppresses the growth of 4T1 breast cancer cells in vivo and in vitro. Chem Biol Interact 2022; 365:110087.
21. Chanu KD, Sharma N, Kshetrimayum V, Chaudhary SK, Ghosh S, Haldar PK, et al. Ageratina adenophora (Spreng.) King & H. Rob. Standardized leaf extract as an antidiabetic agent for type 2 diabetes: An in vitro and in vivo evaluation. Front Pharmacol 2023; 14:1178904.
22. Mahmoud HM, Abdel‐Razik ARH, Elrehany MA, Othman EM, Bekhit AA. Modified citrus pectin (MCP) confers a renoprotective effect on early‐stage nephropathy in type‐2 diabetic mice. Chem Biodivers 2024; 21:e202400104.
23. Khairani AC, Wijayanti T, Widodo GP. Antihyperglycemic activity of red fruit oil (Pandanus conoideus Lam) on improving kidney function in STZ-NA-induced nephropathy rats. J Farm Dan Ilmu Kefarmasian Indones. 2023; 10:173–183.
24. Noei Razliqi R, Ahangarpour A, Mard SA, Khorsandi L. Gentisic acid protects against diabetic nephropathy in Nicotinamide-Streptozotocin administered male mice by attenuating oxidative stress and inflammation: The role of miR-200a/Keap1/Nrf2 pathway, renin-angiotensin system (RAS) and NF-кB. Chem Biol Interact 2023; 380:110507.
25. Huang Y, Liu W, Liu J, Guo D, Zhang P, Liu D, et al. Association of urinary sodium excretion and diabetic kidney disease in patients with type 2 diabetes mellitus: A cross-sectional study. Front Endocrinol 2021; 12:772073.
26. Franken GA, Adella A, Bindels RJ, de Baaij JH. Mechanisms coupling sodium and magnesium reabsorption in the distal convoluted tubule of the kidney. Acta Physiol 2021; 231:e13528.
27. Hu G, Jousilahti P, Peltonen M, Lindström J, Tuomilehto J. Urinary sodium and potassium excretion and the risk of type 2 diabetes: a prospective study in Finland. Diabetologia 2005; 48:1477-1483.
28. Palmer BF, Clegg DJ. Electrolyte and acid–base disturbances in patients with diabetes mellitus. N Engl J Med 2015; 373:548-559.
29. Apperloo EM, Tuttle KR, Pavo I, Haupt A, Taylor R, Wiese RJ, et al. Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: Pooled post hoc analysis from the randomized active- and placebo-controlled SURPASS-1–5 clinical trials. Diabetes Care 2025; 48:430-436.
30. Mahboob S. Electrolytes and Na-K-ATPase: Potential risk factors for the development of diabetic nephropathy. Pak J Pharm Sci 2008; 21:172-179.
31. Zhou L, Yu J, Cai X, Zhu Y, Li M, Han X, et al. Risk factors for progression to albuminuria in individuals with newly diagnosed type 2 diabetes: a 5-year cohort study. BMC Endocr Disord 2025; 25:203.
32. Wang L, Wang H-l, Lan H-y. TGF-β signaling in diabetic nephropathy: An update. Diabet Nephropath  2022; 2:7-16.
33. Olatunde A, Saravanan K, Ogunro OB, Obidola MS, Jakwa A, Lawal A, et al. Insights into diabetic nephropathy biomarkers with focus on existing indices and potential future developments. Discov Med 2025; 2:121.
34. Wang H-Q, Wang S-S, Chiufai K, Wang Q, Cheng X-L. Umbelliferone ameliorates renal function in diabetic nephropathy rats through regulating inflammation and TLR/NF-κB pathway. Chin J Nat Med 2019; 17:346-354.
35. Xu G-K, Sun C-Y, Qin X-Y, Han Y, Li Y, Xie G-Y, et al. Effects of ethanol extract of Bombax ceiba leaves and its main constituent mangiferin on diabetic nephropathy in mice. Chin J Nat Med  2017; 15:597-605.
36. Sas KM, Lin J, Wang C-H, Zhang H, Saha J, Rajendiran TM, et al. Renin-angiotensin system inhibition reverses the altered triacylglycerol metabolic network in diabetic kidney disease. Metabolomics 2021; 17:65.
37. Atwa AM, Abd El-Ghafar OA, Hassanein EH, Mahdi SE, Sayed GA, Alruhaimi RS, et al. Candesartan attenuates cisplatin-induced lung injury by modulating oxidative stress, inflammation, and TLR-4/NF-κB, JAK1/STAT3, and Nrf2/HO-1 signaling. Pharmaceuticals 2022; 15:1222.
38. Chen C-M, Juan S-H, Chou H-C. Hyperglycemia activates the renin-angiotensin system and induces epithelial-mesenchymal transition in streptozotocin-induced diabetic kidneys. J Renin Angiotensin Aldosterone Syst 2018; 19:1470320318803009.
39. Jiang M, Yang Z, Lyu L, Shi M. Dapagliflozin attenuates renal fibrosis by suppressing angiotensin II/TGFβ signaling in diabetic mice. J Diabetes Complications 2024; 38:108687.
40. Naaman SC, Bakris GL. Diabetic nephropathy: Update on pillars of therapy slowing progression. Diabetes Care 2023; 46:1574-1586.
41. Li M, Popovic Z, Chu C, Reichetzeder C, Pommer W, Krämer BK, et al. Impact of angiopoietin-2 on kidney diseases. Kidney Dis 2023; 9:143-156.
42. Paeng J, Park J, Um JE, Nam BY, Kang H-Y, Kim S, et al. The locally activated renin-angiotensin system is involved in albumin permeability in glomerular endothelial cells under high glucose conditions. Nephrol Dial Transplant  2017; 32:61-72.
43. Zhang Q, Yu K, Cao Y, Luo Y, Liu Y, Zhao C. MiR-125b promotes the NF-κB-mediated inflammatory response in NAFLD via directly targeting TNFAIP3. Life Sci 2021; 270:119071.
44. Huang Y-F, Zhang Y, Liu C-X, Huang J, Ding G-H. microRNA-125b contributes to high glucose-induced reactive oxygen species generation and apoptosis in HK-2 renal tubular epithelial cells by targeting angiotensin-converting enzyme 2. Eur Rev Med Pharmacol Sci 2016; 20: 4055-4062.
45. Hussein SM, Khodir SA, Amer GS, Abd El-aziz N, Abu-zeid AY, Elkholy AM, et al. Albiflorin mitigates diabetic nephropathy in rats by down-regulation of TLR4/NF-kB signaling pathway. Med Updates 2025;25:75-87.
46. Lei L, Zhao J, Liu X-Q, Chen J, Qi X-M, Xia L-L, et al. Wogonin alleviates kidney tubular epithelial injury in diabetic nephropathy by inhibiting PI3K/Akt/NF-κB signaling pathways. Drug Des Devel Ther 2021:3131-3150.
47. Feng Q, Yu X, Xie J, Liu F, Zhang X, Li S, et al. Phillygenin improves diabetic nephropathy by inhibiting inflammation and apoptosis via regulating TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways. Phytomedicine 2025; 136:156314.
48. Wang Y, Wang Q, Wang M, Wang X, Liu Q, Lv S, et al. Epigallocatechin‐3‐Gallate Ameliorates Diabetic Kidney Disease by Inhibiting the TXNIP/NLRP3/IL‐1β Signaling Pathway. Food Sci Nutr 2024; 12:10800-10815.
49. Wang H, Li J, Gai Z, Kullak-Ublick GA, Liu Z. TNF-α deficiency prevents renal inflammation and oxidative stress in obese mice. Kidney Blood Press Res 2017; 42:416-427.
50. Zhu Y, Kang D, Bai X, Luo P, Du B, Li B. Plasma zinc levels in patients with diabetic nephropathy: is there a relationship with NLRP3 inflammasome activation and renal prognosis? Biol Trace Elem Res 2025; 203:2550-2560.
51. Wang J, Feng Y, Zhang Y, Liu J, Gong L, Zhang X, et al. TNF-α and IL-1β promote renal podocyte injury in T2DM rats by decreasing glomerular VEGF/eNOS expression levels and altering hemodynamic parameters. J Inflamm Res2022:6657-6673.
52. Reddy VKK, Shiddapur G, Jagdale N, Kondapalli MP, Adapa S. Investigating Interleukin-6 levels in type 2 diabetes mellitus patients with and without diabetic nephropathy. Cureus 2024; 16:e67014.
53. Hai Y, Lee A, Chen K, Kahaly G. Traditional Chinese medicine in thyroid-associated orbitopathy. J Endocrinol Invest 2023; 46:1103-1113.
54. Zhang Y, Qu Y, Cai R, Gao J, Xu Q, Zhang L, et al. Atorvastatin ameliorates diabetic nephropathy through inhibiting oxidative stress and ferroptosis signaling. Eur J Pharmacol 2024; 976:176699.
55. Hashemi M, Zandieh MA, Ziaolhagh S, Mojtabavi S, Sadi FH, Koohpar ZK, et al. Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective. Biochim Biophys Acta Mol Basis Dis 2023; 1869:166714.
56. Suzuki T, Yamamoto M. Molecular basis of the Keap1–Nrf2 system. Free Radic Biol Med 2015; 88:93-100.
57. Zhang J, Zhang M, Tatar M, Gong R. Keap1-independent Nrf2 regulation: A novel therapeutic target for treating kidney disease. Redox Bio 2025:103593.
58. Zhang J, Zhao D, Zang Z, Ruan Z, Fu Q, Zhang K. MiR-200a-3p-enriched MSC-derived extracellular vesicles reverse erectile function in diabetic rats by targeting Keap1. Biomed Pharmacother 2024; 177:116964.
59. Abdelmonem M, Ibrahim SM, Essam RM, Amin HAA, Abd‐Elmawla MA. Lutein exerts its cardioprotective effect against the experimental model of isoprenaline‐induced myocardial infarction via MIAT/miR‐200a/Nrf2/TXINP pathway. J Biochem Mol Toxicol  2021; 35:e22899.
60. Zhao X-J, Yu H-W, Yang Y-Z, Wu W-Y, Chen T-Y, Jia K-K, et al. Polydatin prevents fructose-induced liver inflammation and lipid deposition through increasing miR-200a to regulate Keap1/Nrf2 pathway. Redox Biol 2018; 18:124-137.
61. Lianhong X, Weixia S, Wei L, Yanbo L. Diabetic nephropathy treatment by Zn supplementation in a murine model of type 1 diabetes mellitus: Potential role of Nrf2 signaling pathway. Sichuan Da Xue Xue Bao Yi Xue Ban 2025; 56:613-618.
62. Sifuentes-Franco S, Padilla-Tejeda DE, Carrillo-Ibarra S, Miranda-Díaz AG. Oxidative stress, apoptosis, and mitochondrial function in diabetic nephropathy. Int J Endocrinol 2018; 2018:1875870.
63. El Tabaa MM, El Tabaa MM, Rashad E, Elballal MS, Elazazy O. Harmine alleviated STZ-induced rat diabetic nephropathy: A potential role via regulating AMPK/Nrf2 pathway and deactivating ataxia-telangiectasia mutated (ATM) signaling. Int Immunopharmacol 2024; 132:111954.
64. Unuofin JO, Lebelo SL. Anti-oxidant effects and mechanisms of medicinal plants and their bioactive compounds for the prevention and treatment of type 2 diabetes: an updated review. Oxid Med Cell Longev 2020; 2020:1356893.
65. Shu-Ping L, Yu-Wen W, Sheng-Lan Q, Yun-Peng Z, Deng G, Wen-Zheng D, et al. Analogous β-carboline alkaloids harmaline and harmine ameliorate scopolamine-induced cognition dysfunction by attenuating acetylcholinesterase activity, oxidative stress, and inflammation in mice. Front Pharmacol 2018; 9:346.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 26 September 2026